<div>
  <p>
  </p>
  <ul>
    <li>
      <p>
        AstraZeneca has launched a new health technology business called Evinova, which aims to bring digital health solutions into clinical research. The company plans to utilize established digital technologies to enhance the design and delivery of clinical trials, with the goal of reducing time and cost in medical development.
      </p>
    </li>
    <li>
      <p>
        Evinova's suite of digital solutions includes a unified trial solution that enables data collection through digital endpoints and connected medical devices, virtual visits, medicine delivery to patients, telehealth, remote monitoring, and sample tracking. Additionally, it will offer an AI-assisted study design and planning module to help to craft better studies and provide cost estimates and operational viability assessments in real time.&nbsp;
      </p>
    </li>
    <li>
      <p>
        Evinova notes that its clinical trial solutions have already been tested in AstraZeneca-sponsored trials conducted in over 40 countries and are available in 80 languages. The company will be spread across nine countries and will launch with a staff of 300. Evinova also notes that it has already signed agreements with contract research organizations Parexel and Fortrea, who have both agreed to offer the company&rsquo;s solutions to its customers.&nbsp;
      </p>
    </li>
    <li>
      <p>
        <b>Analyst QuickTake: </b>
        This move by AstraZeneca follows the general industry trend of incumbents in the Clinical Trial Technology space, where they elect to develop in-house solutions to address industry issues. Examples include 
        <a href="https://sp-edge.com/companies/2555">
          Oracle
        </a>
        &rsquo;s Oracle Health Sciences department for clinical trial management solutions and 
        <a href="https://sp-edge.com/companies/201465">
          Microsoft
        </a>
        &rsquo;s Azure-based solutions for patient recruitment, data management, and analysis. Some of the main issues highlighted by incumbents are with regard to trial participation and efficient clinical trial design, with Evinova&rsquo;s solution directly helping industry players resolve the latter.&nbsp;&nbsp;&nbsp;
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.astrazeneca.com/media-centre/articles/2023/astrazeneca-launches-a-healthtech-business-evinova.html">
      Press release
    </a>
  </p>
  <p>
    <a href="https://www.mobihealthnews.com/news/astrazeneca-launches-evinova-bring-ai-clinical-trials">
      Mobi Health News
    </a>
  </p>
  <p>
    <a href="https://www.fiercebiotech.com/cro/astrazeneca-launches-new-company-share-digital-clinical-trial-expertise-cros-pharmas">
      Fierce Healthcare
    </a>
  </p>
  <p>
  </p>
</div>


Clinical Trial Technology

ANALYST_QUICK_TAKE

INCUMBENTS_PRESENT

PROMINENT_CATEGORY

<p>AstraZeneca has launched a new health technology business called Evinova, which aims to bring digital health solutions into clinical research. The company plans to utilize established digital technologies to enhance the design and delivery of clinical trials, with the goal of reducing time and cost in medical development.</p><p>Evinova's suite of digital solutions includes a unified trial solution that enables data collection through digital endpoints and connected medical devices, virtual visits, medicine delivery to patients, telehealth, remote monitoring, and sample tracking. Additionally, it will offer an AI-assisted study design and planning module to help to craft better studies and provide cost estimates and operational viability assessments in real time.&nbsp;</p><p>Evinova notes that its clinical trial solutions have already been tested in AstraZeneca-sponsored trials conducted in over 40 countries and are available in 80 languages. The company will be spread across nine countries and will launch with a staff of 300. Evinova also notes that it has already signed agreements with contract research organizations Parexel and Fortrea, who have both agreed to offer the company’s solutions to its customers.&nbsp;</p><p><strong>Analyst QuickTake: </strong>This move by AstraZeneca follows the general industry trend of incumbents in the Clinical Trial Technology space, where they elect to develop in-house solutions to address industry issues. Examples include <a href="https://sp-edge.com/companies/2555">Oracle </a>’s Oracle Health Sciences department for clinical trial management solutions and <a href="https://sp-edge.com/companies/201465">Microsoft </a>’s Azure-based solutions for patient recruitment, data management, and analysis. Some of the main issues highlighted by incumbents are with regard to trial participation and efficient clinical trial design, with Evinova’s solution directly helping industry players resolve the latter.&nbsp;&nbsp;&nbsp;</p>

AstraZeneca launches new business ‘Evinova’ to enhance clinical trials

DISRUPTOR_PRESENT

<div>
 <ul>
  <li><p>Clinical trial management technology provider ObvioHealth has partnered with Chemist Warehouse, the largest retail pharmacy chain in Australia, to improve the reach and efficiency of clinical trials.</p></li>
  <li><p>Chemist Warehouse will promote ObvioHealth-managed trials to its customers in Australia through offline and online channels. ObvioHealth will use Chemist Warehouse's Telehealth services for studies that require clinician assessments. The partnership aims to increase awareness and convenience of clinical trials, addressing participant recruitment hurdles. The long-term goal is to expedite the introduction of innovative therapies to the market efficiently and economically.</p></li>
 </ul>
</div>

ObvioHealth partners with Chemist Warehouse to enhance clinical trial recruitment in Australia

<div>
 <ul>
  <li><p>IQVIA, a healthcare and life science technology provider, is planning to raise USD 500 million through an offering of senior secured notes due 2029. This will bring the total funds raised by the company to USD 1.5 billion.</p></li>
  <li><p>The funds raised will be used to settle certain outstanding term loans and restructure previous credit facilities into a new term B loan valued at USD 1.25 billion. Additionally, the funds will cover fees and expenses associated with the loan agreements and the term B loan. </p></li>
  <li><p>Following the note offering and loan restructuring, IQVIA plans to enter into currency swap agreements to mitigate exposure to its USD-based loan facilities.</p></li>
  <li><p>IQVIA offers various platforms for healthcare and life sciences, including clinical trial planning, compliance, real-world evidence, and patient engagement. It is a subsidiary of IQVIA Holdings Inc. (NYSE:IQV), a publicly listed healthcare technology company.</p></li>
 </ul>
</div>

IQVIA raises USD 500 million in debt funding to repay existing debt

<div>
 <ul>
  <li><p>ClinOne, a clinical trial management platform provider, has raised an additional $2 million in funding, following its Series A round held in April. This brings the company's total funds raised to approximately $10 million. Boulder Ventures and Highpoint Ventures co-led the extension round.</p></li>
  <li><p>The newly acquired funds will be used to expand ClinOne's operations and business reach.</p></li>
  <li><p>Following the funding, Katherine Vandebelt and JeanMarie Markham have been appointed to ClinOne's board. Both individuals are Life Science leaders and will contribute their experience and strategic insights to support the company's planned growth.</p></li>
  <li><p>As of November 2023, ClinOne's platform is currently utilized in 60 countries by over 80 sponsors, contract research organizations, and site networks.</p></li>
 </ul>
</div>

ClinOne raises USD 2 million in Series A extension

The HTML represents a div containing an unordered list with three list items. The list items contain paragraphs with information about PhaseV, a trial design and data analysis platform provider. 

The first list item states that PhaseV has raised $15 million in a funding round led by Viola Ventures and Exor Ventures, with participation from LionBird and angel investors. 

The second list item mentions that the raised funds will be used to expand PhaseV's operations and development efforts. 

The third list item provides more details about PhaseV's specialization in machine-learning technology for optimizing clinical trial design and analysis. It mentions that their platform also helps analyze and interpret data during ongoing trials in order to refine and optimize the trials for adaptive trials.

PhaseV raises USD 15 million in funding

<div>
 <ul>
  <li><p>Flatiron Health partners with Penn Medicine's Abramson Cancer Center (ACC) to provide advanced cancer care insights to oncology care clinicians.</p></li>
  <li><p>ACC clinicians can access evidence-based treatment recommendations and promote site-preferred pathways and clinical trials at the point of care using Flatiron Assist. This platform is integrated into the EHR system and offers the latest evidence-based medicine, treatment pathways, and clinical research.</p></li>
 </ul>
</div>

Flatiron Health and Penn Medicine partner for advanced cancer care

Mendel has released a new product called Hypercube, which is an AI co-pilot designed for life sciences and healthcare organizations. Hypercube uses everyday language to analyze patient data and provides fast insights and answers to complex questions. It combines large language modeling with symbolic AI to overcome the limitations of standard data querying methods. Hypercube allows users to interrogate structured and unstructured data using plain English questions and offers query visualization and programmatic access for advanced users. The product is currently available for early adopters and will be officially launched in Q1 2024.

Mendel.ai launches Hypercube, an AI co-pilot for real world data applications

H1 has launched GenosAI, an AI tool that is embedded into its Trial Landscape platform. Trial Landscape helps analyze complex inquiries related to clinical trials, and GenosAI offers various features such as insights into competing trials, streamlining site selection, promoting diversity in clinical trials, and improving trial design. H1 is a provider of several platforms that assist with different aspects of clinical trials, and its Trial Landscape platform generates insights based on a large amount of data from trials, publications, healthcare providers, patients, and claims.

H1 launches GenAI tool to accelerate clinical trials

Healthcare technology company Mednet has introduced a software update to its iMednet eClinical platform, which includes electronic consent capabilities. The new eConsent module allows researchers to collect and store participant consent electronically, making the process easier and more accessible. It also includes embedded media to enhance participant comprehension. According to Mednet, this addition strengthens their ability to support various types of clinical trials across all therapeutic areas. Mednet's iMednet platform provides a range of tools for designing, conducting, and managing clinical trials, including electronic data capture, trial management, and eConsent.

Mednet launches eConsent functionality

Clinical trial management platform provider, Thread, has expanded its partnership with data connectivity company Datavant to launch a tokenization feature for clinical trial and real-world data. This allows biopharmaceutical companies to link and analyze patient records across de-identified datasets while maintaining patient privacy. The tokenization feature can be configured in Thread's study builder and securely connects clinical trial data with real-world data sources. This integration of clinical and real-world data provides a comprehensive view of the patient journey and facilitates the generation of evidence for research studies.

All Updates